Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06507852 · ClinicalTrials.gov registry record
A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia
A clinical trial of Hypercholesterolemia and Atherosclerotic Cardiovascular Disease, sponsored by Novartis.
- Completed
- Registry status
- 95
- Enrollment target
- 1
- Study location
NCT06507852: Completed study of Hypercholesterolemia and Atherosclerotic Cardiovascular Disease, sponsored by Novartis.
NCT06507852 is a study of Hypercholesterolemia and Atherosclerotic Cardiovascular Disease that has completed, run by Novartis. The registered enrollment target is 95 participants, below the 815-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06507852, a study of Hypercholesterolemia and Atherosclerotic Cardiovascular Disease, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 95 participants
- Enrollment target
- 1
- Study location
Study Summary
This was a descriptive, non-interventional, retrospective cohort study among patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia, ASCVD-risk equivalent (ASCVD-RE) or familial hypercholesterolemia (FH) administered inclisiran in a real-world setting in Austria.
Primary Outcome
Time intervals: * Time from Dose 1 to Dose 2: 5 months or less. * Time from Dose 2 to Dose 3: * Less than 6 months. * Between 6 months and 9 months. * Greater than 9 months.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2023-07-06 |
What the finished NCT06507852 record still lists
NCT06507852 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 815-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Hypercholesterolemia appearing as the primary indexed condition, and to 0 interventions.
NCT06507852 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06507852 about?
NCT06507852 is a clinical study titled "A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia". This was a descriptive, non-interventional, retrospective cohort study among patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia, ASCVD-risk equivalent (ASCVD-RE) or familial hypercholesterolemia (FH) administered inclisiran in a real-world setting in Austria.
What is the current status of trial NCT06507852?
This trial is currently completed. The enrollment target is 95 participants. The study started on 2022-10-03. Estimated completion is 2023-07-06.
What conditions does trial NCT06507852 study?
This clinical trial studies the following conditions: Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.
Who is sponsoring clinical trial NCT06507852?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06507852 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06507852's enrollment target sits among peer trials
95 42nd of 62 higher than 21 of 62 other Hypercholesterolemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypercholesterolemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacokinetics of Butyrate Tablet BKR-017
RECRUITING
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
RECRUITING · NA
-
Pharmacogenomic Informed Statin Prescribing
RECRUITING · NA
-
Causes and Natural History of Dyslipidemias
RECRUITING
-
A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI